Cellomatics underpins continued US and European expansion with two business development hires

Cellomatics Biosciences, a Nottingham-based preclinical contract research organisation, continues to expand its global client base by adding two new members of staff to support its business development efforts.

The company has welcomed Dr Pier Giorgio Amendola and Dr Jyoti Mundra to assist the company with its expansion into both European and US markets.

A key challenge for UK-based CROs operating internationally is managing cultural differences and regional market dynamics. Pier will use his experience to navigate these challenges in European markets and build strong local partnerships. He will be focused on identifying new business opportunities, building and nurturing relationships with key stakeholders, and enhancing Cellomatics' market footprint.

Of joining Cellomatics, Pier says, “Cellomatics provides a dynamic, science-driven environment that allows for close collaboration with clients and the delivery of tailored, innovative solutions. Having been a client of Cellomatics in my previous roles, I value its high scientific standards and am eager to promote its capabilities to new clients, accelerating their drug development pipelines.”

The US is one of the biggest and most fast-growing biotech markets globally and Cellomatics is eager to further its client base here, following its recent export achievements. The timing of Jyoti’s appointment could not be better as the US looks to work with new markets following the recent BIOSECURE Act.

Jyoti is based in New Jersey, US and brings over 15 years of experience working in a business development role at large US-based CROs. Her experience will be a valuable asset to Cellomatics as she assists with accelerating the company’s growth while enhancing its presence and business within the US.

Jyoti says: “I am excited to bring my extensive business and scientific experience to help expand the customer base and to provide the opportunity for US clients to benefit from Cellomatics pre-clinical expertise.”

Of the two new appointments, Cellomatics’ CEO and founder Shailendra Singh adds: “Having worked with Pier for a number of years through Dompé we are delighted that he has decided to join the Cellomatics team in a Business Development role.

“His experience working in the pharmaceutical sector has given him a deep understanding of our client needs and this will be key in building new relationships and achieving Cellomatics’ growth goals.

“I am also thrilled to welcome Jyoti to the Cellomatics team. Her wealth of experience in executive leadership roles, deep understanding of the US market and its work culture will be an invaluable asset to Cellomatics and I look forward to working closely with her.”

For more information, visit: www.cellomaticsbio.com